3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
CNS
1
Conditions
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Osteosarcoma
1
Neuroblastoma
1
Central Nervous System Neoplasms
1
Brain Neoplasms
1
Interventions
Temozolomide
58
Radiotherapy
50
Carmustine
23
Carboplatin
18
Filgrastim
17
Chemotherapy, Adjuvant
17
Irinotecan
12
Surgical Procedures, Operative
11
Peripheral Blood Stem Cell Transplantation
11
O(6)-benzylguanine
10
Magnetic Resonance Spectroscopy
10
Drug Therapy
10
Etoposide
9
sargramostim
8
Thiotepa
8
Thalidomide
8
Cyclophosphamide
8
Bevacizumab
8
Procarbazine
7
Gene Expression Profiling
7
Erlotinib Hydrochloride
7
Radiation
6
Everolimus
6
Cisplatin
6
motexafin gadolinium
5
aldesleukin
5
Topotecan
5
Imatinib Mesylate
5
Celecoxib
5
Busulfan
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Central Nervous System Neoplasms
×
IL32 protein, human
×
Sarcoma
×
Clear all
NCT02100891
2025-03-19
STIR
Medical College of Wisconsin
Phase 2
Terminated
15 enrolled
11 charts